1. Home
  2. ERH vs RLYB Comparison

ERH vs RLYB Comparison

Compare ERH & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Utilities and High Income Fund

ERH

Allspring Utilities and High Income Fund

HOLD

Current Price

$11.60

Market Cap

107.4M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$16.54

Market Cap

86.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ERH
RLYB
Founded
2004
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.4M
86.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ERH
RLYB
Price
$11.60
$16.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.7K
19.8K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
8.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
6.16
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.69
Revenue Growth
N/A
43.00
52 Week Low
$11.50
$0.48
52 Week High
$13.07
$17.57

Technical Indicators

Market Signals
Indicator
ERH
RLYB
Relative Strength Index (RSI) 37.70 56.64
Support Level $11.54 $15.68
Resistance Level $11.96 $17.34
Average True Range (ATR) 0.10 0.49
MACD -0.01 0.01
Stochastic Oscillator 4.49 58.67

Price Performance

Historical Comparison
ERH
RLYB

About ERH Allspring Utilities and High Income Fund

Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: